Ishikawa Chitose, Tsutamoto Takayoshi, Fujii Masanori, Sakai Hiroshi, Tanaka Toshinari, Horie Minoru
Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu, Japan.
Circ J. 2006 Jul;70(7):857-63. doi: 10.1253/circj.70.857.
The prognostic role of serum C-reactive protein (CRP) in chronic heart failure (CHF) patients, especially those with nonischemic dilated cardiomyopathy (DCM), remains unknown. In the present study, whether CRP provides prognostic information in DCM patients was evaluated.
Neurohumoral factors and hemodynamics in 84 consecutive DCM patients were measured and these patients were followed up for a mean period of 42 months. During the follow-up period, 23 patients developed cardiac events and 18 patients died of cardiac causes. Using stepwise multivariate Cox proportional hazards regression analyses, log brain natriuretic peptide (BNP) (p = 0.007) and high-sensitivity CRP (hsCRP) > 1 mg/L (p = 0.008) were significant independent predictors of cardiac events. The patients were stratified into 4 groups based on the normal serum concentration of hsCRP (1 mg/L) and median plasma concentration of BNP (110 pg/ml). Survival rates were significantly higher in patients with hsCRP < 1 mg/L and BNP < 110 pg/ml. The hazard ratio of patients with BNP > 110 pg/ml and hsCRP > 1 mg/L was 15.8 (95% confidence interval, 1.9-127.2) compared with those with BNP < 110 pg/ml and hsCRP < 1 mg/L for cardiac death.
Serum hsCRP level is an independent prognostic predictor in patients with DCM and the combination of hsCRP and BNP may be useful for the management of CHF patients with DCM.
血清C反应蛋白(CRP)在慢性心力衰竭(CHF)患者,尤其是非缺血性扩张型心肌病(DCM)患者中的预后作用尚不清楚。在本研究中,评估了CRP是否能为DCM患者提供预后信息。
对84例连续的DCM患者的神经体液因子和血流动力学进行了测量,并对这些患者进行了平均42个月的随访。在随访期间,23例患者发生心脏事件,18例患者死于心脏原因。使用逐步多变量Cox比例风险回归分析,对数脑钠肽(BNP)(p = 0.007)和高敏CRP(hsCRP)>1 mg/L(p = 0.008)是心脏事件的显著独立预测因子。根据hsCRP正常血清浓度(<1 mg/L)和BNP血浆中位数浓度(110 pg/ml)将患者分为4组。hsCRP<1 mg/L且BNP<110 pg/ml的患者生存率显著更高。与BNP<110 pg/ml且hsCRP<1 mg/L的患者相比,BNP>110 pg/ml且hsCRP>1 mg/L的患者心脏死亡的风险比为15.8(95%置信区间,1.9 - 127.2)。
血清hsCRP水平是DCM患者的独立预后预测指标,hsCRP和BNP的联合检测可能有助于DCM合并CHF患者的管理。